Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 9, 2013, Pages 756-762

  Liu, Shiguo ^a   Fang, Yue ^b   Shen, Huiling ^b   Xu, Wenlin ^b   Li, Hao ^b  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Berberine; miR 21; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS REGULATORY PROTEIN; BERBERINE; CISPLATIN; MICRORNA; MIRN21 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; RNA BINDING PROTEIN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CELL SURVIVAL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MIR-21; MUTATION; OVARY CANCER; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

BERBERINE; MIR-21; OVARIAN CANCER;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BERBERINE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA-BINDING PROTEINS;

EID: 84883241973     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt075     Document Type: Article

References (32)

1. Brewer MA, Johnson K, Follen M, Gershenson D and Bast R, Jr. Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 2003, 9: 20-30.
2. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60: 277-300.
3. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM and Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007, 6: 609-621.
4. Schwartz PE. Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res 2002, 107: 99-118.
5. Davidson B, Reich R, Trope CG, Wang TL and Shih Ie M. New determinates of disease progression and outcome in metastatic ovarian carcinoma. Histol Histopathol 2010, 25: 1591-1609.
6. Inoue K, Kulsum U, Chowdhury SA, Fujisawa S, Ishihara M, Yokoe I and Sakagami H. Tumor-specific cytotoxicity and apoptosis-inducing activity of berberines. Anticancer Res 2005, 25: 4053-4059.
7. Katiyar SK, Meeran SM, Katiyar N and Akhtar S. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinog 2009, 48: 24-37.
8. Tong N, Zhang J, Chen Y, Li Z, Luo Y, Zuo H and Zhao X. Berberine sensitizes mutliple human cancer cells to the anticancer effects of doxorubicin in vitro. Oncol Lett 2012, 3: 1263-1267.
9. Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C and Feng S, et al. Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS One 2011, 6: e23427.
10. Hsu YL, Kuo PL, Chiang LC and Lin CC. Isoliquiritigenin inhibits the proliferation and induces the apoptosis of human non-small cell lung cancer a549 cells. Clin Exp Pharmacol Physiol 2004, 31: 414-418.
11. Yan XD, Li M, Yuan Y, Mao N and Pan LY. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Oncol Rep 2007, 17: 1163-1169.
12. Hu H, Li Y, Gu J, Zhu X, Dong D, Yao J and Lin C, et al. Antisense oligonucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells. Leuk Lymphoma 2010, 51: 694-701.
13. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT and Barbisin M, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005, 33: e179.
14. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25: 402-408.
15. He B, Tong X, Wang L, Wang Q, Ye H, Liu B and Hong X, et al. Tramadol and flurbiprofen depress the cytotoxicity of cisplatin via their effects on gap junctions. Clin Cancer Res 2009, 15: 5803-5810.
16. Bai H, Xu R, Cao Z, Wei D and Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 2011, 585: 402-408.
17. Rabik CA and Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33: 9-23.
18. Johnstone RW, Ruefli AA and Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108: 153-164.
19. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008, 111: 478-486.
20. Solar P and Sytkowski AJ. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780. Cancer Lett 2011, 309: 11-18.
21. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y and Deguchi T, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008, 377: 114-119.
22. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F and Visone R, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103: 2257-2261.
23. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133: 647-658.
24. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT and Jiang J, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130: 2113-2129.
25. Li Y, Li W, Yang Y, Lu Y, He C, Hu G and Liu H, et al. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 2009, 1286: 13-18.
26. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T and Takahata S, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009, 8: 1067-1074.
27. Cai X, Hagedorn CH and Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004, 10: 1957-1966.
28. Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, Sakurai K and Iba H. miR-21 Gene expression triggered by AP-1 is sustained through a doublenegative feedback mechanism. JMol Biol 2008, 378: 492-504.
29. Kuo HP, Chuang TC, Tsai SC, Tseng HH, Hsu SC, Chen YC and Kuo CL, et al. Berberine, an isoquinoline alkaloid, inhibits the metastatic potential of breast cancer cells via Akt pathway modulation. J Agric Food Chem 2012, 60: 9649-9658.
30. Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H and Matsuhashi S, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA 1999, 96: 14037-14042.
31. Yang HS, Knies JL, Stark C and Colburn NH. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 2003, 22: 3712-3720.
32. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E and Kidani A, et al. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009, 69: 3148-3156.